Hypofractionated Accelerated Radiotherapy with Concurrent Carboplatin for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Clinical Oncology

Volumn 23, Issue 1, 2011, Pages 34-39

  Chan, A K ^a   Sanghera, P ^a   Choo, B A ^a   McConkey, C ^b   Mehanna, H ^c   Parmar, S ^a   Pracy, P ^a   Glaholm, J ^a   Hartley, A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Acceleration; Carboplatin; Head and neck carcinoma; Hypofractionation; Radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEEDING DISORDER; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78650417677     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.07.015     Document Type: Article

References (27)

1. Pignon J., Bourhis J., Domenge C., Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 355:949-955.
2. Pignon J., Le Maitre A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
3. Budach W., Hehr T., Budach V., Belka C., Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006, 6:28.
4. James N.D., Robertson G., Squire C.J., Forbes H., Jones K., Cottier B. A national audit of radiotherapy fractionation in head and neck cancer. J Clin Oncol 2003, 15:41-46.
5. Ho K.F., Fowler J.F., Sykes A.J., Yap B.K., Lee L.W., Slevin N.J. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Acta Oncol 2009, 48:431-439.
6. Fowler J.F. Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling. Clin Oncol (R Coll Radiol) 2007, 19:8-22.
7. Fowler J.F. Optimum overall times II: extended modelling for head and neck radiotherapy. Clin Oncol (R Coll Radiol) 2008, 20:113-126.
8. Madhava K., Hartley A., Wake M., Watkinson J.C., Glaholm J. Carboplatin and hypofractionated accelerated radiotherapy: a dose escalation study of an outpatient chemoradiation schedule for squamous cell carcinoma of the head and neck. Clin Oncol (R Coll Radiol) 2006, 18:77-81.
9. Sanghera P., McConkey C., Ho K.F., Glaholm J., Hartley A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2007, 67:1342-1351.
10. Dische S., Saunders M., Barrett A., Harvey A., Gibson D., Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997, 44:123-136.
11. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992, 25:231-241.
12. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomised study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16.
13. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91:2081-2086.
14. Jeremic B., Milicic B., Dagovic A., Vaskovic Z., Tadic L. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2004, 22:3540-3548.
15. Bourhis J., Calais G., Lapeyre M., et al. Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomised trials of the French Head and Neck Group (GORTEC). Semin Oncol 2004, 31:822-826.
16. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionation irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338:1798-1804.
17. Staar S., Rudat V., Steutzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of multicentric randomised German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001, 50:1161-1171.
18. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004, 22:4665-4673.
19. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose escalated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective trial. J Clin Oncol 2005, 23:1125-1135.
20. Eisbruch A., Harris J., Garden A., et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2010, 76:1333-1338.
21. Gupta N.K., Swindell R. Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial. Clin Oncol (R Coll Radiol) 2001, 13:339-344.
22. Tobias J., Monson K., Gupta N., et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol 2010, 11:66-74.
23. Sykes A., Slevin N.J., MacDougall R.H., Ironside J.A., Mais K.L. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiother Oncol 2004, 71:81-84.
24. Koukourakis M.I., Tsoutsou P.G., Karpouzis A. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2010, 77:9-15.
25. Khalil A.A., Bentzen S.M., Bernier J., et al. Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head and neck carcinomas. Int J Radiat Oncol Biol Phys 2003, 55:568-575.
26. Newman L., Vieira F., Schwiezer V., et al. Eating and weight changes following chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngeal Head Neck Surg 1998, 124:589-592.
27. Denham J.W., Peters L.J., Johansen J., et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?. Radiother Oncol 1999, 52:157-164.